The clinical course and its correlated immune status in COVID-19 pneumonia
•The immune status is significantly different between severe and non-severe COVID-19.•The decrease of T lymphocyte correlated with the course of patients with COVID-19.•The level of T lymphocyte is an indicator for severity and prognosis of COVID-19. To explore the clinical course and its dynamic fe...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical virology 2020-06, Vol.127, p.104361-104361, Article 104361 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 104361 |
|---|---|
| container_issue | |
| container_start_page | 104361 |
| container_title | Journal of clinical virology |
| container_volume | 127 |
| creator | He, Ruyuan Lu, Zilong Zhang, Lin Fan, Tao Xiong, Rui Shen, Xiaokang Feng, Haojie Meng, Heng Lin, Weichen Jiang, Wenyang Geng, Qing |
| description | •The immune status is significantly different between severe and non-severe COVID-19.•The decrease of T lymphocyte correlated with the course of patients with COVID-19.•The level of T lymphocyte is an indicator for severity and prognosis of COVID-19.
To explore the clinical course and its dynamic features of immune status in COVID-19 patients and find predictors correlated with severity and prognosis of COVID-19.
The electronic medical records of 204 patients with COVID-19 pneumonia confirmed by nucleic acid testing were retrospectively collected and analyzed.
All patients were divided into severe (69) and non-severe group (135). Lymphocyte subsets count, including CD3+ T cell, CD4+ T cell, CD8+ T cell, B cell (CD19+) and NK cell (CD16+ 56+), were significantly lower in severe group (P＜0.001). The dynamic levels of T lymphocyte in severe group were significantly lower from disease onset, but in the improved subgroup the value of T lymphocyte began to increase after about 15-day treatment and finally returned to the normal level. The cut-off value of the counts of CD3+ (576), CD4+ (391) and CD8+ (214) T cell were calculated and indicated significantly high sensitivity and specificity for severity of COVID-19.
Our results shown that the decrease of CD3+, CD4+ and CD8+ T lymphocyte correlated with the course of patients with COVID-19 pneumonia, especially in severe cases. The level of T lymphocyte could be used as an indicator for prediction of severity and prognosis of patients with COVID-19 pneumonia. The application of glucocorticoid should be cautious in severe cases. |
| doi_str_mv | 10.1016/j.jcv.2020.104361 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7152870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1386653220301037</els_id><sourcerecordid>2396310314</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-26f3282b5f2faab3c35960a8243edde276c41a4d499245881cf890184f9292913</originalsourceid><addsrcrecordid>eNp9UU1PwzAMjRCIjcEP4IJ65NIRJ2mbCgkJja8hJC7ANcpSFzK16UjaSfx7Mg0QXJAP9pOfny0_Qo6BToFCfracLs16yijbYMFz2CFjkAVPszIvdmPNZZ7mGWcjchDCklLIuCj2yYgzLgRndEzun94wMY111ugmMd3gAybaVYntQ4TeY6N7jLBtB4dJ6HU_hMS6ZPb4Mr9KoUxWDoe2c1Yfkr1aNwGPvvKEPN9cP83u0ofH2_ns8iE1IoM-ZXnNmWSLrGa11gtueLyWaskEx6pCVuRGgBaVKEsmMinB1LKkIEVdshjAJ-Riq7saFi1WBl3vdaNW3rbaf6hOW_W34-ybeu3WqoCMyYJGgdMvAd-9Dxh61dpgsGm0w24IivEy50A5iEiFLdX4LgSP9c8aoGrjgVqq6IHaeKC2HsSZk9_3_Ux8Pz0SzrcEjF9aW_QqGIvOYGU9ml5Vnf1H_hOZBpYr</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2396310314</pqid></control><display><type>article</type><title>The clinical course and its correlated immune status in COVID-19 pneumonia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>He, Ruyuan ; Lu, Zilong ; Zhang, Lin ; Fan, Tao ; Xiong, Rui ; Shen, Xiaokang ; Feng, Haojie ; Meng, Heng ; Lin, Weichen ; Jiang, Wenyang ; Geng, Qing</creator><creatorcontrib>He, Ruyuan ; Lu, Zilong ; Zhang, Lin ; Fan, Tao ; Xiong, Rui ; Shen, Xiaokang ; Feng, Haojie ; Meng, Heng ; Lin, Weichen ; Jiang, Wenyang ; Geng, Qing</creatorcontrib><description>•The immune status is significantly different between severe and non-severe COVID-19.•The decrease of T lymphocyte correlated with the course of patients with COVID-19.•The level of T lymphocyte is an indicator for severity and prognosis of COVID-19.
To explore the clinical course and its dynamic features of immune status in COVID-19 patients and find predictors correlated with severity and prognosis of COVID-19.
The electronic medical records of 204 patients with COVID-19 pneumonia confirmed by nucleic acid testing were retrospectively collected and analyzed.
All patients were divided into severe (69) and non-severe group (135). Lymphocyte subsets count, including CD3+ T cell, CD4+ T cell, CD8+ T cell, B cell (CD19+) and NK cell (CD16+ 56+), were significantly lower in severe group (P＜0.001). The dynamic levels of T lymphocyte in severe group were significantly lower from disease onset, but in the improved subgroup the value of T lymphocyte began to increase after about 15-day treatment and finally returned to the normal level. The cut-off value of the counts of CD3+ (576), CD4+ (391) and CD8+ (214) T cell were calculated and indicated significantly high sensitivity and specificity for severity of COVID-19.
Our results shown that the decrease of CD3+, CD4+ and CD8+ T lymphocyte correlated with the course of patients with COVID-19 pneumonia, especially in severe cases. The level of T lymphocyte could be used as an indicator for prediction of severity and prognosis of patients with COVID-19 pneumonia. The application of glucocorticoid should be cautious in severe cases.</description><identifier>ISSN: 1386-6532</identifier><identifier>EISSN: 1873-5967</identifier><identifier>DOI: 10.1016/j.jcv.2020.104361</identifier><identifier>PMID: 32344320</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Aged ; Betacoronavirus ; Coronavirus Infections - complications ; Coronavirus Infections - immunology ; COVID-19 ; Electronic Health Records ; Female ; Humans ; immunity ; Lymphocyte Count ; lymphocyte subsets ; Lymphocyte Subsets - immunology ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral - complications ; Pneumonia, Viral - immunology ; Prognosis ; Retrospective Studies ; SARS-CoV-2 ; Severity of Illness Index ; T-Lymphocyte Subsets - immunology</subject><ispartof>Journal of clinical virology, 2020-06, Vol.127, p.104361-104361, Article 104361</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><rights>2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-26f3282b5f2faab3c35960a8243edde276c41a4d499245881cf890184f9292913</citedby><cites>FETCH-LOGICAL-c451t-26f3282b5f2faab3c35960a8243edde276c41a4d499245881cf890184f9292913</cites><orcidid>0000-0003-0870-9893</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1386653220301037$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32344320$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>He, Ruyuan</creatorcontrib><creatorcontrib>Lu, Zilong</creatorcontrib><creatorcontrib>Zhang, Lin</creatorcontrib><creatorcontrib>Fan, Tao</creatorcontrib><creatorcontrib>Xiong, Rui</creatorcontrib><creatorcontrib>Shen, Xiaokang</creatorcontrib><creatorcontrib>Feng, Haojie</creatorcontrib><creatorcontrib>Meng, Heng</creatorcontrib><creatorcontrib>Lin, Weichen</creatorcontrib><creatorcontrib>Jiang, Wenyang</creatorcontrib><creatorcontrib>Geng, Qing</creatorcontrib><title>The clinical course and its correlated immune status in COVID-19 pneumonia</title><title>Journal of clinical virology</title><addtitle>J Clin Virol</addtitle><description>•The immune status is significantly different between severe and non-severe COVID-19.•The decrease of T lymphocyte correlated with the course of patients with COVID-19.•The level of T lymphocyte is an indicator for severity and prognosis of COVID-19.
To explore the clinical course and its dynamic features of immune status in COVID-19 patients and find predictors correlated with severity and prognosis of COVID-19.
The electronic medical records of 204 patients with COVID-19 pneumonia confirmed by nucleic acid testing were retrospectively collected and analyzed.
All patients were divided into severe (69) and non-severe group (135). Lymphocyte subsets count, including CD3+ T cell, CD4+ T cell, CD8+ T cell, B cell (CD19+) and NK cell (CD16+ 56+), were significantly lower in severe group (P＜0.001). The dynamic levels of T lymphocyte in severe group were significantly lower from disease onset, but in the improved subgroup the value of T lymphocyte began to increase after about 15-day treatment and finally returned to the normal level. The cut-off value of the counts of CD3+ (576), CD4+ (391) and CD8+ (214) T cell were calculated and indicated significantly high sensitivity and specificity for severity of COVID-19.
Our results shown that the decrease of CD3+, CD4+ and CD8+ T lymphocyte correlated with the course of patients with COVID-19 pneumonia, especially in severe cases. The level of T lymphocyte could be used as an indicator for prediction of severity and prognosis of patients with COVID-19 pneumonia. The application of glucocorticoid should be cautious in severe cases.</description><subject>Adult</subject><subject>Aged</subject><subject>Betacoronavirus</subject><subject>Coronavirus Infections - complications</subject><subject>Coronavirus Infections - immunology</subject><subject>COVID-19</subject><subject>Electronic Health Records</subject><subject>Female</subject><subject>Humans</subject><subject>immunity</subject><subject>Lymphocyte Count</subject><subject>lymphocyte subsets</subject><subject>Lymphocyte Subsets - immunology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - complications</subject><subject>Pneumonia, Viral - immunology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>SARS-CoV-2</subject><subject>Severity of Illness Index</subject><subject>T-Lymphocyte Subsets - immunology</subject><issn>1386-6532</issn><issn>1873-5967</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1PwzAMjRCIjcEP4IJ65NIRJ2mbCgkJja8hJC7ANcpSFzK16UjaSfx7Mg0QXJAP9pOfny0_Qo6BToFCfracLs16yijbYMFz2CFjkAVPszIvdmPNZZ7mGWcjchDCklLIuCj2yYgzLgRndEzun94wMY111ugmMd3gAybaVYntQ4TeY6N7jLBtB4dJ6HU_hMS6ZPb4Mr9KoUxWDoe2c1Yfkr1aNwGPvvKEPN9cP83u0ofH2_ns8iE1IoM-ZXnNmWSLrGa11gtueLyWaskEx6pCVuRGgBaVKEsmMinB1LKkIEVdshjAJ-Riq7saFi1WBl3vdaNW3rbaf6hOW_W34-ybeu3WqoCMyYJGgdMvAd-9Dxh61dpgsGm0w24IivEy50A5iEiFLdX4LgSP9c8aoGrjgVqq6IHaeKC2HsSZk9_3_Ux8Pz0SzrcEjF9aW_QqGIvOYGU9ml5Vnf1H_hOZBpYr</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>He, Ruyuan</creator><creator>Lu, Zilong</creator><creator>Zhang, Lin</creator><creator>Fan, Tao</creator><creator>Xiong, Rui</creator><creator>Shen, Xiaokang</creator><creator>Feng, Haojie</creator><creator>Meng, Heng</creator><creator>Lin, Weichen</creator><creator>Jiang, Wenyang</creator><creator>Geng, Qing</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0870-9893</orcidid></search><sort><creationdate>20200601</creationdate><title>The clinical course and its correlated immune status in COVID-19 pneumonia</title><author>He, Ruyuan ; Lu, Zilong ; Zhang, Lin ; Fan, Tao ; Xiong, Rui ; Shen, Xiaokang ; Feng, Haojie ; Meng, Heng ; Lin, Weichen ; Jiang, Wenyang ; Geng, Qing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-26f3282b5f2faab3c35960a8243edde276c41a4d499245881cf890184f9292913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Betacoronavirus</topic><topic>Coronavirus Infections - complications</topic><topic>Coronavirus Infections - immunology</topic><topic>COVID-19</topic><topic>Electronic Health Records</topic><topic>Female</topic><topic>Humans</topic><topic>immunity</topic><topic>Lymphocyte Count</topic><topic>lymphocyte subsets</topic><topic>Lymphocyte Subsets - immunology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - complications</topic><topic>Pneumonia, Viral - immunology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>SARS-CoV-2</topic><topic>Severity of Illness Index</topic><topic>T-Lymphocyte Subsets - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>He, Ruyuan</creatorcontrib><creatorcontrib>Lu, Zilong</creatorcontrib><creatorcontrib>Zhang, Lin</creatorcontrib><creatorcontrib>Fan, Tao</creatorcontrib><creatorcontrib>Xiong, Rui</creatorcontrib><creatorcontrib>Shen, Xiaokang</creatorcontrib><creatorcontrib>Feng, Haojie</creatorcontrib><creatorcontrib>Meng, Heng</creatorcontrib><creatorcontrib>Lin, Weichen</creatorcontrib><creatorcontrib>Jiang, Wenyang</creatorcontrib><creatorcontrib>Geng, Qing</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>He, Ruyuan</au><au>Lu, Zilong</au><au>Zhang, Lin</au><au>Fan, Tao</au><au>Xiong, Rui</au><au>Shen, Xiaokang</au><au>Feng, Haojie</au><au>Meng, Heng</au><au>Lin, Weichen</au><au>Jiang, Wenyang</au><au>Geng, Qing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The clinical course and its correlated immune status in COVID-19 pneumonia</atitle><jtitle>Journal of clinical virology</jtitle><addtitle>J Clin Virol</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>127</volume><spage>104361</spage><epage>104361</epage><pages>104361-104361</pages><artnum>104361</artnum><issn>1386-6532</issn><eissn>1873-5967</eissn><abstract>•The immune status is significantly different between severe and non-severe COVID-19.•The decrease of T lymphocyte correlated with the course of patients with COVID-19.•The level of T lymphocyte is an indicator for severity and prognosis of COVID-19.
To explore the clinical course and its dynamic features of immune status in COVID-19 patients and find predictors correlated with severity and prognosis of COVID-19.
The electronic medical records of 204 patients with COVID-19 pneumonia confirmed by nucleic acid testing were retrospectively collected and analyzed.
All patients were divided into severe (69) and non-severe group (135). Lymphocyte subsets count, including CD3+ T cell, CD4+ T cell, CD8+ T cell, B cell (CD19+) and NK cell (CD16+ 56+), were significantly lower in severe group (P＜0.001). The dynamic levels of T lymphocyte in severe group were significantly lower from disease onset, but in the improved subgroup the value of T lymphocyte began to increase after about 15-day treatment and finally returned to the normal level. The cut-off value of the counts of CD3+ (576), CD4+ (391) and CD8+ (214) T cell were calculated and indicated significantly high sensitivity and specificity for severity of COVID-19.
Our results shown that the decrease of CD3+, CD4+ and CD8+ T lymphocyte correlated with the course of patients with COVID-19 pneumonia, especially in severe cases. The level of T lymphocyte could be used as an indicator for prediction of severity and prognosis of patients with COVID-19 pneumonia. The application of glucocorticoid should be cautious in severe cases.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32344320</pmid><doi>10.1016/j.jcv.2020.104361</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-0870-9893</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6532 |
| ispartof | Journal of clinical virology, 2020-06, Vol.127, p.104361-104361, Article 104361 |
| issn | 1386-6532 1873-5967 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7152870 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Betacoronavirus Coronavirus Infections - complications Coronavirus Infections - immunology COVID-19 Electronic Health Records Female Humans immunity Lymphocyte Count lymphocyte subsets Lymphocyte Subsets - immunology Male Middle Aged Pandemics Pneumonia, Viral - complications Pneumonia, Viral - immunology Prognosis Retrospective Studies SARS-CoV-2 Severity of Illness Index T-Lymphocyte Subsets - immunology |
| title | The clinical course and its correlated immune status in COVID-19 pneumonia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T23%3A41%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20clinical%20course%20and%20its%20correlated%20immune%20status%20in%20COVID-19%20pneumonia&rft.jtitle=Journal%20of%20clinical%20virology&rft.au=He,%20Ruyuan&rft.date=2020-06-01&rft.volume=127&rft.spage=104361&rft.epage=104361&rft.pages=104361-104361&rft.artnum=104361&rft.issn=1386-6532&rft.eissn=1873-5967&rft_id=info:doi/10.1016/j.jcv.2020.104361&rft_dat=%3Cproquest_pubme%3E2396310314%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2396310314&rft_id=info:pmid/32344320&rft_els_id=S1386653220301037&rfr_iscdi=true |